Purpose: To investigate the changes of IGF system in colon cancer patients in relation to age, the serum IGF-I, IGF-II, IGFBP2, IGFBP3 and ALS were measured by immunochemistry before surgery, as well as one and six months after surgery. Material and Methods: One hundred and twenty six patients were included into the study: group I (<50 yrs, N=21); group II (50 to <55 yrs, N=16) ; group III (55 to <65 yrs, N=34); group IV (65 to <75 yrs, N=42) and group V (≥75 yrs, N=13). Results: Before surgery: only the mean value of IGF-I concentration in group I was significantly higher as compared to group V (p<0.01). One month after surgery: 1) a decrease in the mean values of IGF-I, IGF-II, IGFBP3 and ALS levels was observed, but only for IGF-II (groups II-V), IGFBP3 (groups II-V) and ALS (groups III-V) the changes were significant; 2) the mean value of ALS level in group I was higher as compared to group III-V (p<0.05 to 0.02); 3) higher mean values of IGF-I/alb, IGFBP3/alb and ALS/alb were noted for group I as compared to group V (p<0.01 to 0.001); 4) the mean levels of IGFBP2 were significantly lower in group I as compared to groups II, III, IV and V (p<0.001 in all cases). Conclusions: In colon cancer patients IGF-I, IGFBP3 and ALS decrease with age, but the relation between them exists regardless the patient's age and time of observation. Lower IGFBP2 level together with higher IGF-I might contribute to more aggressive course of disease in colon cancer patients below 50 years of age.
INTRODUCTION
Epidemiological data link IGF system with the risk of cancer. It has been postulated that IGF-I concentration at the upper normal range and IGFBP3 values at lower normal range predict the subsequent development of colorectal cancer [1] . It is known that aging proceeds more quickly with higher levels of IGF-related signaling [2, 3] . The circulating IGFs are bound to IGFBPs, mainly IGFBP3, forming a 150 kDa ternary complex with acid labile subunit (ALS) [4] . It is known that the levels of both IGF-I and IGFBP3 are relatively stable within individuals, but vary considerably between normal individuals because of differences in physical activity, BMI, and diet [5, 6] . The binding proteins not only modulate the bioavailability of IGF-I and IGF-II for the receptors, but also greatly prolong the circulating half-life of IGFs. Bioavailability of IGFs is influenced by the levels of specific IGFBPs [7] . IGF-I play a critical role in cellular survival and proliferation. Elevated circulating IGF-I levels have been associated with an increased risk of colorectal cancer. Interactions among insulin, IGF-I and its binding proteins in the context of colorectal carcinogenesis provide a potential mechanism through which the diet and the associated lifestyle factors may increase the risk of this type of cancer.
The results of different studies on IGF axis in colon cancer patients are difficult to compare. This is mainly due to differences concerning the population used and the complexity of molecular mechanisms, which could explain the possible connection of IGFs and their binding proteins not only with carcinogenesis but also with the progression of colorectal Group cancer. One of the reasons of inconsistent interpretation is a complex interaction among different factors: physical activity, diet and nutritional status. All these factors may influence the concentrations of IGFs and IGFBPs in the circulation. It is also known that in healthy subjects plasma levels of the components of IGF system are related to age, sex and BMI, and that there are considerable inter-individual and intraindividual variations [8] [9] [10] . Pre-analytical and analytical problems connected with the measurement of IGFs and IGFBPs concentrations in blood serum frequently lead to controversial conclusions. Data concerning the relationship between age and serum IGF-I and IGFBP3 levels in a general adult population have been published recently [11] , but for patients with colon cancer no such data are available. The data from the literature focus mainly on IGF system long before and at the time of diagnosing adenoma or cancer, but no data exist regarding the IGF system components in colon cancer patients before surgery and during one year follow up in relation to age. or serum albumin level below 33 g/L was accepted as a limit of malnutrition. Although such low values of albumin were noted in 5.6% of patients and such a low BMI in 4.7% of patients, none of the studied patients had both, very low albumin level and very low BMI.
MATERIAL AND METHODS
In all studied patients, plasma levels of IGF-I (RIA, Biosource, Belgium), IGF-II and IGFBP3 (IRMA, Diagnostic Systems Laboratory, USA), IGF-BP2 (RIA, Diagnostic Systems Laboratory, USA), and acid labile subunit (ALS) (ELISA, Diagnostic Systems Laboratory, USA) were measured in serum samples before and one, six and twelve months after the surgery. Morning venous blood samples were taken after overnight fasting. Each blood sample was centrifuged within no more than 60 minutes after collection and serum was immediately separated, frozen and stored at -20 º C until assayed, but no longer than 4 months. Each serum sample was divided into eight portions to avoid refreezing. All pre-analytical steps were strictly controlled. Sensitivity of the assays was as follows: 8.7 ng/ml for IGF-I, 12.0 ng/ml for IGF-II, 0.03 ng/ml for free IGF, 21.0 ng/ml for IGFBP2, 0.5 µg/ml for IGFBP3 and 0.7 µg/ml for ALS. The intra-and inter-assay coefficients of variations for each measurement were <8% and <10%, respectively. Serum albumin level was determined by dry chemistry method (Vitros 950, Johnson & Johnson) .
Statistical analysis
The data were presented in the form including typical statistics (mean, SE, and 95% CI). For each patient the concentrations of all measured parameters were also expressed as the ratio to albumin level (IGFs/alb, IGFBPs/alb). To evaluate the differences between the groups for every parameter, a repeated measurement one-way ANOVA test was performed. The statistical significant difference between the groups was calculated by using unpaired Student's t-test (the determinants of all the parameters studied were normally distributed). The correlations were expressed as Pearson's coefficient. A twotailed p value of ≤0.05 was accepted as indicating statistical significance. All statistical analyses were performed with Graph Pad PRISM 4.0.
RESULTS

IGF-I, IGF-II, IGFBP2, IGFBP3, and ALS in colon cancer patients before surgery
Before surgery a statistically significant negative correlation was found between the age and the concentrations of IGF-I (p<0.01), IGFBP3 (p<0.04) and ALS (p<0.02), and positive correlation between age and IGFBP2 (p<0.05). The highest mean values of IGF-I concentration (and higher 95% CI of mean) were found for groups I and II before surgery. In group III and group IV patients these values were insignificantly lower as compared to group I and group II. A significant difference between the mean levels of IGF-I was only between groups I and V (p<0.01) (Tab. 2; Fig. 1A ). Similar trend of changes was observed for the mean values of IGFBP3 and ALS, but without significant differences between the groups studied ( Fig. 2A, 2B) . The mean values of IGF-II and IGFBP2 concentration did not differ with age, although in the case of IGFBP2 the lowest values were noted for group I.
IGF-I, IGF-II, IGFBP2, IGFBP3, and ALS in colon cancer patients one and six months after surgery
One month after surgery a decrease in the mean values of IGF-I, IGF-II, IGFBP3 and ALS was noted for all age groups as compared to the corresponding values before surgery, with the lowest decrease (5-9%, on average) for group I and the highest (20-30 %, on average) for group V (Fig. 1A, 1B ; Fig.  2A, 2B) . However, no statistically significant differences were noted between the mean values of IGF-I one month after surgery and the corresponding values before surgery. When analyzing all the patients as one group, a decrease of mean IGF-I level after surgery, as compared to the value before surgery, was statistically significant (p<0.001). One month after surgery the mean value of IGF-I concentration for group V was significantly lower as compared to group I and group II. In contrast, the mean values of IGFBP3 and ALS one month after surgery were significantly lower for all the groups except group I ( Fig. 2A, 2B) , as compared to the values before surgery. The mean levels of ALS one month after surgery were significantly lower in groups III (p<0.03), IV (p<0.02) and V (p<0.002) as compared to the value noted for group I. Six and twelve months after surgery the mean concentrations of IGF-I, IGF-II, IGFBP3 and ALS did not differ from the respective values before surgery. The mean values obtained 12 months after surgery are not shown in Fig. 1, 2 and 3 for none of the parameters measured because 33.3% of the patients died within one year.
Except for group I, one month after surgery the mean levels of IGFBP2 had higher values as compared to the corresponding values before surgery, but significant differences were only for groups III and IV (p<0.001 for both cases) (Fig. 3A) . The mean values for groups II, III, IV and V were significantly higher as compared to the value obtained for group I (p<0.001-0.005) (Fig. 3A) . Six and twelve months after surgery the mean values did not differ from the corresponding values noted before surgery.
IGF-I to IGFBP3 ratio
Regardless of the group studied and the time of observation, no differences between the mean values of IGF-I/IGFBP3 ratio were observed. Fig. 1a and 1b, Fig. 2a and 2b and Fig. 3a present the mean values of IGFs and IGFBPs level expressed as the ratio to albumin (IGFs/alb, IGFBPs/alb) in relation to age and time of observation. One month after surgery, unlike the changes in the mean values of concentration, the mean values of IGF-I/alb, IGF-II/alb, IGFBP3/alb and ALS/alb were higher than or did not differ from the values obtained before surgery. A significant difference was found only in the case of IGF-I/alb and IGF-II/ alb in group I (Fig. 1a, 1b) . Also, the mean value of IGF-I/ alb obtained for group I after surgery was significantly higher as compared to the mean value noted for group V (p<0.001). No changes for IGF-II/alb ratio were found at any time of observation. One month after surgery significant differences in mean values were noted for IGFBP3/alb (Fig. 2a) . The mean values of this ratio were significantly higher in groups I and II as compared to groups IV and V (p<0.01 in all cases), as well as in group III vs. group V (p<0.001). For ALS/alb significantly higher mean values one month after surgery were noted for groups I and II as compared to those for group V (p<0.01 in both cases) (Fig. 2b) .
The ratio of IGF-I, IGF-II, IGFBP2, IGFBP3 and ALS levels to albumin
The changes observed for IGFBP2/alb ratio were similar to those of IGFBP2 concentration. An exception made a statistically significant increase in the mean values of IGFBP2/ alb observed for groups II-V (p<0.001), but not for group I (Fig. 3a) , as compared to the corresponding values before surgery. Also the values for groups II-V were significantly higher than those for group I (p<0.001). For all the groups, six and twelve months after surgery the mean values were almost identical to the corresponding values noted before surgery.
DISCUSSION
Many clinical, laboratory, as well as, epidemiological studies, link the IGF system with colorectal cancer [14] [15] [16] . Unfortunately, most of the data are difficult to compare not only due to the complexity of the IGF system. There are other aspects which should be taken into consideration before the clearly cut statement on the role of IGF system in cancer risk and progression can be made. Looking from the laboratory point of view, two problems must be solved: the IGFs and IGFBPs reference intervals for adult population and the analytical aspects of the measurement of IGF axis components. The latter problem stems from the fact that most components of human endocrine system, including IGFs and IGFBPs, are measured by immunochemical methods which differ in precision and accuracy, as well as susceptibility to many interferences. Looking from the clinical point of view, physical condition of the patient, accompanying diseases, hormonal status, stage of the disease, tumor localization, medical treatment etc. should be taken into account. Any relation of the concentration of the analytes to age must also be considered. In another words, the question of "when" and "how" the analyte is measured must first be evaluated.
Age-dependent changes of IGF-I and IGFBP3 in healthy peoples of older age have been already published [10, 11, 17] . The same trend emerges from the results of the present study: a decrease in IGF-I, IGFBP3 and ALS concentrations with age can also be observed in colon cancer patients. It is only the trend which can be considered, because, as for almost all components of the endocrine system, it is not quite appropriate to do any comparison between the studies using population based reference intervals. Another problem in the evaluation of the role of IGF axis system in colorectal cancer lies in the nature of immunochemical methods. In addition to poor comparability between different reagent kits, the problem of heterogeneity of the measured components of IGF system and the known problem of interferences from the presence of heterophilic antibodies has never been carefully studied. This problem is important, because the presence of different autoantibodies and/or heterophilic antibodies in serum or plasma samples increases with age.
Another problem with proper interpretation of the results of the determination of IGF system components is connected with clinical state of patients. Many critical illnesses are responsible for changes in endocrine system. It is known that surgery is one of the conditions causing a decrease in IGF-I, IGFBP3 and ALS concentrations [18] . Caloric restriction does not affect IGFBP3 or IGFBP3 proteolytic activity but causes a decrease in IGF-I levels [19] as it was also seen in the present study one month after surgery. According to the published data, low levels of IGFBP3 detected in advanced malignancy may be a consequence of an increased tumor driven proteolysis [20] . IGFBP3 degraded by proteolysis has a reduced affinity for IGF-I and IGF-II, but its ability to form ternary complexes with ALS is fully maintained. Acid-labile subunit (ALS) does not by itself bind IGF-I, but is necessary to form the complex with IGF-I-IGFBP3 and, like IGF-I and IGFBP3, is primarily under control of the growth hormone (GH) [21, 22] . Except in critically ill patients [23, 24] , ALS is relatively independent of the mechanisms known to influence the secretion of IGF-I and IGFBP3 [25] . ALS also increases the affinity of IGF-I to degraded, but not intact, IGFBP3 [26] .
The observed decrease in IGF-I, IGF-II, IGFBP3 and ALS levels one month after surgery was not seen when the results were presented as the ratio to albumin. This suggests that the changes are due to nonspecific effects of surgery. Together with a decrease of albumin, a negative acute phase protein, the observed tendency might be due not only to the diminished synthetic function of the liver but also to hemodilution. Our data suggest that in the colon cancer patients both IGFBP3/ alb and ALS/alb values were not influenced by surgery, although extensive proteolysis of IGFBP3 has been reported in critically ill patients, as well as following major abdominal surgery [26] [27] [28] . This may suggest that an increase in IGF-I/ alb observed one month after surgery is not related to the failure of forming ternary complexes with IGFBP3 and ALS. Synthesis of IGF-II also takes place in the liver but is not tightly regulated by GH. This explains why almost no changes in IGF-II concentration were seen in our patients in relation to age and time of observation. In older colon cancer patients (65 years or more) a significantly lower IGFBP3/alb and ALS/alb ratio one month after surgery as compared to the values noted in younger patients may be explained by general declining of endocrine function in older patients and/or the more frequent presence of inflammation.
In human colon cancer the amount of IGFBP2 in the circulation is often elevated [29] . This was also confirmed in our study. The mean level of IGFBP2 for all the studied patients was twice as high as compared to the laboratory reference range for healthy adults aged 55 to 75 years (data not shown). IGFBP2 is up-regulated in conditions such as starvation or trauma. This explains a significant increase in IGFBP2 concentration after surgery. Interestingly, the smallest increase one month after surgery was seen in the patients below 55 years of age and the value was significantly lower as compared to groups II-V. It was suggested that IGFBP-2 inhibits IGF-I and IGF-II action, so the lack of increase in IGFBP-2 one month after surgery in group I could be responsible for higher IGFs. The exact reason why this takes place only in young patients is not clear. From the clinical point of view it is known that in younger colon cancer patient the course of disease is more aggressive. It is tempting to speculate, that one of the reasons of it is the enhanced proteolysis of IGFBP2 in younger patients which might lead to an increase in free IGF-I , having easier access to extravascular space. Increased bioavailability of IGF-I, with its mitogenic and antiapoptotic effects, may be one of the factors responsible for faster tumor progression at any stage [30] . It is not known whether this is the case only in younger colon cancer patients. It might be the case, because increased serum IGFBP1 and IGFBP2 are inversely associated with colorectal cancer risk [31] .
CONCLUSIONS
The present study shows that in colon cancer patients the correlation between IGF-I, IGFBP3 and ALS exists regardless of the patient's age and time of observation, and that IGF-I, IGFBP3 and ALS decrease with age. It can be speculated that in patients below 50 years the lowest IGFBP2 together with the elevated IGF-I might be the reason of more aggressive course of the disease. Also, any conclusion concerning the relation of IGF system to the risk and/or progression of colon cancer should be considered separately for younger (below 50 years of age) and older patients.
